Overview
BIO-TECHNE Corporation is a global life-sciences company that develops, manufactures and sells reagents, analytical instruments and related products for research, diagnostics and bioprocessing. Its two core segments are Protein Sciences, which provides biological reagents and protein-analysis tools, and Diagnostics and Spatial Biology, which supplies diagnostic assays and controls, spatial-biology products, and genetic and oncology kits. Its product portfolio includes cytokines, growth factors, antibodies and automated protein-analysis systems, sold under brands including R&D Systems, Tocris Bioscience, Novus Biologicals and ProteinSimple.[1][2][3][4]
The company describes its mission as improving quality of life by catalyzing advances in science and medicine.[5] For the fiscal year ended June 30, 2026, Bio-Techne reported consolidated net sales of approximately $1.215 billion.[6] It reports approximately 3,100 employees worldwide and operations in 34 locations, reflecting a global presence across its research and diagnostic markets.[7][5] [1][2][3][4][5][6][7][5][7]
Products & services
BIO-TECHNE’s FY2026 product portfolio includes reagents and tools for life-science research and cell and gene therapy. Its Protein Sciences products include specialized proteins such as cytokines and growth factors, antibodies, small molecules, tissue-culture sera, cell-selection technologies, cGMP-manufactured proteins and small molecules, and Wilson Wolf cell-culture devices. Brands named in the FY2026 filing include R&D Systems, Tocris Biosciences, and Novus Biologicals.[3]
Its analytical tools include manual plate-based immunoassays, automated multiplex immunoassays, and automated western blotting and isoelectric-focusing systems for analyzing complex protein samples. Some immunoassays have FDA marketing clearance as in-vitro diagnostic devices. The Simple Western platform automates capillary electrophoresis and immunoassay detection; Jess supports chemiluminescent or fluorescent detection, while Ella/Simple Plex measures up to eight analytes simultaneously.[4][8][9][10]
Diagnostics & Spatial Biology products include diagnostic controls, calibrators and assays, genetic and oncology kits, and tissue-based in-situ hybridization assays and instruments. ACD’s RNAscope detects transcriptome, DNA copy, and structural variation in intact cells while preserving tissue context at single-cell resolution. Lunaphore COMET combines precision microfluidics with automated RNAscope assays and antibodies to detect multiple protein and RNA biomarkers on one slide.[11][12]
In FY2026, Protein Sciences generated $874.620 million, or about 72.2%, of the two reported segments’ combined sales; Diagnostics & Spatial Biology generated $336.365 million, or about 27.8%. These percentages are calculated from the segment sales reported in the filing; it does not provide a product-level revenue mix.[13] [3][4][11][12][13][13][8][9][10][8][9][10]
Geographic presence
In FY2026, Bio-Techne reported net sales of $1,215.0 million by customer destination. The United States accounted for $635.4 million (52.3%); EMEA excluding the UK, $294.2 million (24.2%); the UK, $56.3 million (4.6%); APAC excluding Greater China, $85.8 million (7.1%); Greater China, $104.1 million (8.6%); and the rest of the world, $39.3 million (3.2%). Percentages are calculated as shares of total net sales.[14] The company reports two product-based operating segments rather than geographic segments.[2]
The company describes an operating footprint spanning North America, Europe and Asia, with manufacturing locations in North America, the UK, Canada, Switzerland and China. Minneapolis is its global headquarters.[15] Disclosed facilities include sites in the United States, China, the UK, Switzerland, Canada, Ireland, France and Germany; the company also reports approximately 3,100 employees and operations in 34 locations worldwide.[16][17][18][19] A geographic breakdown of employees is not provided. [14][2][15][16][17][18][19]
Business segments
Bio-Techne reports two operating segments. Protein Sciences generated $874.6 million, approximately 72.0% of FY2026 consolidated net sales. It supplies biological reagents for life-science research, diagnostics, and cell and gene therapy, as well as proteomic analysis tools. Its offerings include cytokines, growth factors, antibodies, small molecules, tissue-culture sera, cell-selection technologies, and automated western blot and multiplexed ELISA systems; the segment comprises Reagent Solutions and Analytical Solutions.[11][20][3]
Diagnostics and Spatial Biology generated $336.4 million, approximately 27.7% of FY2026 consolidated net sales. Its diagnostic business supplies controls, calibrators, and assays—including hematology, blood-chemistry, blood-gas, and coagulation products—while its spatial biology business offers tissue-based in-situ hybridization assays and instrumentation for analyzing tissue and genetic material. The segment also includes genetic and oncology kits for research and clinical use.[11][21][22][12] Percentages use consolidated net sales as the denominator; the company does not separately report revenue for the underlying divisions.[13] [11][20][3][21][22][12][13]
Company history
Research and Diagnostic Systems, Inc. (R&D Systems) was founded in Minneapolis in 1976. It introduced its first product, a platelet-rich-plasma control, the following year. In 1985, Techne Corporation acquired R&D Systems, establishing the public-company roots of the business.[23][24][25]
During the 2000s and early 2010s, the company broadened its research-reagent and diagnostics offerings through acquisitions including Fortron Bio Science and BiosPacific in 2005, Tocris in 2011, Boston Biochem assets in 2011, and Bionostics in 2013. Charles Kummeth became CEO in 2013.[26][27][28][29][30]
In 2014, Techne adopted Bio-Techne as its trade name and acquired businesses including ProteinSimple and Novus Biologicals, adding protein-analysis instruments, antibodies and research reagents. Subsequent acquisitions expanded its capabilities into RNA in-situ hybridization with Advanced Cell Diagnostics in 2016, exosome-based molecular diagnostics with Exosome Diagnostics in 2018, and single-cell sorting with Namocell in 2022. In 2023, the acquisition of Lunaphore further expanded its spatial-biology tools.[31][32][33][34][35][36][37]
Kim Kelderman succeeded Kummeth as President and CEO in February 2024. In June 2026, Bio-Techne agreed to be acquired by Merck KGaA; shareholders approved the agreement in September, while regulatory approvals remained outstanding as of the reported update.[38][39][40][41] [23][36][37][39][40][24][25][26][27][28][29][30][31][32][33][34][35][38][41]
Sources
- BIO-TECHNE Corp — Full financial report (2026 Y)
- www.bio-techne.com[5]
- investors.bio-techne.com[7]
- www.bio-techne.com[8]
- www.bio-techne.com[9]
- www.bio-techne.com[10]
- www.bio-techne.com[19]
- BIO-TECHNE Corp — Full financial report (2025 Y)
- investors.bio-techne.com[24]
- investors.bio-techne.com[25]
- investors.bio-techne.com[26]
- investors.bio-techne.com[27]
- investors.bio-techne.com[28]
- investors.bio-techne.com[29]
- investors.bio-techne.com[30]
- www.prnewswire.com[31]
- investors.bio-techne.com[32]
- investors.bio-techne.com[33]
- investors.bio-techne.com[34]
- investors.bio-techne.com[35]
- investors.bio-techne.com[38]
- investors.bio-techne.com[41]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore BIO-TECHNE Corp in Finbar ↗